<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: <z:hpo ids='HP_0002665'>Lymphomas</z:hpo> are the third most common <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignant tumor</z:e> in the pediatric age group after <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:mp ids='MP_0009277'>brain tumors</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Outcome has improved remarkably over the past decade because of improvements in imaging and staging systems that more accurately reflect the clinical behavior, and the development of risk adapted multiagent chemotherapeutic regimens </plain></SENT>
<SENT sid="2" pm="."><plain>The aim of this work is to study the outcome, Overall Survival (OS) and Event Free Survival (EFS) of patients receiving FAB LMB96 protocol applied for treatment of mature B cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>PATIENTS AND METHODS: This is a retrospective study analyzing the data of 103 newly diagnosed <z:e sem="disease" ids="C0220612" disease_type="Neoplastic Process" abbrv="">pediatric NHL</z:e> [Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>÷<z:hpo ids='HP_0001909'>leukemia</z:hpo>, Diffuse Large B Cell <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>)] who received LMB96 protocol at Department of Pediatric <z:hpo ids='HP_0002664'>Oncology</z:hpo>, National <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Institute, Cairo University, during the time period from 1st of January 2006 to the end of December 2008 </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 103 patients were included in the study, and were followedup till 31st December 2009 </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: This study included were 80 males (77.7%) and 23 females (22.3%), their mean age was 6.55±3.9 years ranged from 2 to 16 years </plain></SENT>
<SENT sid="6" pm="."><plain>Abdominal presentation was the most common clinical presentation seen in 85 patients (82.5%) followed by thoracic mass in 27 patients (26.2%) and cervical mass in 22 patients (21.4%) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> involvement occurred in 16 patients (15.5%) while bone marrow infiltration occurred in 18 patients (17.5%) </plain></SENT>
<SENT sid="8" pm="."><plain>The most common pathological subtype was Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> seen in 83 patients (80.6%) followed by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> in 12 patients (11.7%) </plain></SENT>
<SENT sid="9" pm="."><plain>Stage III was the most commonly seen; detected in 65 patients (63.1%) </plain></SENT>
<SENT sid="10" pm="."><plain>The commonest treatment group seen was group B in 80 patients (77.7%) followed by group C in 19 patients (18.4%) then group A in 4 patients (3.9%).Complete remission for the whole group of patients was achieved in 72 patients (70%), relapses and disease progression occurred in 9 patients (8.7%) and stable disease in 1 patient (1%) </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0011420'>Death</z:hpo> due to <z:mpath ids='MPATH_681'>septicemia</z:mpath> occurred in 13 patients (12.6%) </plain></SENT>
<SENT sid="12" pm="."><plain>There were 8 patients (7.7%) who discontinued treatment </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: FAB LMB96 protocol is well tolerated, giving results close to the international literature for both group A and B patients, while it seems toxic for group C patients </plain></SENT>
<SENT sid="14" pm="."><plain>KEY WORDS: NHL- FAB LMB96- Pediatric- <z:hpo ids='HP_0002665'>Lymphoma</z:hpo> </plain></SENT>
</text></document>